Rachael Sexton

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Brian G.M. Durie, Antje Hoering, Muneer H. Abidi et al. · The Lancet · 2016 · 888 citations

Medicine, Hematology, Oncology +16

Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)

Brian G.M. Durie, Antje Hoering, Rachael Sexton et al. · Blood Cancer Journal · 2020 · 252 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed et al. · Blood · 2013 · 197 citations

Medicine, Oncology, Radiology +10

Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701)

Carolina Porras, Jesse Nodora, Rachael Sexton et al. · Cancer Causes & Control · 2012 · 143 citations

Medicine, Infectious Diseases, Clinical Epidemiology +6

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial

Saad Z. Usmani, Antje Hoering, Sikander Ailawadhi et al. · The Lancet Haematology · 2020 · 125 citations · Full text

Medicine, Hematology, Pharmacotherapy +13